Salivary Gland Cancer Treatment Market 2026
The Salivary Gland Cancer Treatment Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Salivary Gland Cancer Treatment Market.
This report delivers a comprehensive overview of the Salivary Gland Cancer Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Salivary Gland Cancer Treatment Market. The Salivary Gland Cancer Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Salivary Gland Cancer Treatment Market Scope:
By Type
This report delivers a comprehensive overview of the Salivary Gland Cancer Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Salivary Gland Cancer Treatment Market. The Salivary Gland Cancer Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Salivary Gland Cancer Treatment Market.
This report delivers a comprehensive overview of the Salivary Gland Cancer Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Salivary Gland Cancer Treatment Market. The Salivary Gland Cancer Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Salivary Gland Cancer Treatment Market Scope:
By Type
- Mucoepidermoid Carcinoma
- Adenoid Cystic Carcinoma
- Acinic Cell Carcinoma (Acinic Cell Adenocarcinoma)
- Polymorphous adenocarcinoma
- Pleomorphic Adenoma
- Warthin’s Tumor
- Others
- Physical exam
- Imaging tests
- Biopsy
- Others
- Surgery
- Radiation therapy
- Chemotherapy
- Supportive (palliative) care
- Others
- Hospital
- Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Bristol-Myers Squibb Company
- LGM PHARMA
- Pfizer Inc.
- Bedford Laboratories
- Baxter
- sanofi-aventis U.S. LLC
- Pierre Fabre Medicament
- Antares Pharma, Inc.
- CMS Group
- Sandoz Inc.(LIST NOT EXHAUSTIVE)
This report delivers a comprehensive overview of the Salivary Gland Cancer Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Salivary Gland Cancer Treatment Market. The Salivary Gland Cancer Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Type
3.2. Market Snippet by Diagnosis
3.3. Market Snippet by Treatment
3.4. Market Snippet by End user
3.5. Market Snippet by Distribution Channel
3.6. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing clinical trials and product launches by the market players are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Lack of awareness about the disorder is expected to hamper in the forecast period.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type Segment
7.2. Mucoepidermoid Carcinoma*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Adenoid Cystic Carcinoma
7.4. Acinic Cell Carcinoma (Acinic Cell Adenocarcinoma)
7.5. Polymorphous adenocarcinoma
7.6. Pleomorphic Adenoma
7.7. Warthin’s Tumor
7.8. Others
8. BY DIAGNOSIS
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
8.1.2. Market Attractiveness Index, By Diagnosis Segment
8.2. Physical exam*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Imaging tests
8.3.1. Magnetic resonance imaging (MRI)
8.3.2. Computerized tomography (CT)
8.3.3. Positron emission tomography (PET)
8.3.4. Ultrasound
8.3.5. Others
8.4. Biopsy
8.5. Others
9. BY TREATMENT
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment Segment
9.2. Surgery*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Radiation therapy
9.4. Chemotherapy
9.4.1. Cisplatin
9.4.2. Mitoxantrone
9.4.3. Doxorubicin (Adriamycin)
9.4.4. Epirubicin (Ellence)
9.4.5. Cyclophosphamide (Cytoxan)
9.4.6. Paclitaxel (Taxol)
9.4.7. Docetaxel (Taxotere)
9.4.8. Vinorelbine (Navelbine)
9.4.9. Methotrexate
9.4.10. Others
9.5. Supportive (palliative) care
9.6. Others
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.1.2. Market Attractiveness Index, By End user Segment
10.2. Hospital*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Clinics
10.4. Ambulatory Surgical Centers
10.5. Diagnostic Centers
10.6. Others
11. BY DISTRIBUTION CHANNEL
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Hospital Pharmacy*
11.2.1. Introduction
11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
11.3. Retail Pharmacy
11.4. Online Pharmacy
11.5. Others
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Product Benchmarking
13.4. List of Key Companies to Watch
14. COMPANY PROFILES
14.1. Bristol-Myers Squibb Company*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Key Highlights
14.1.4. Financial Overview
14.2. LGM PHARMA
14.3. Pfizer Inc.
14.4. Bedford Laboratories
14.5. Baxter
14.6. sanofi-aventis U.S. LLC
14.7. Pierre Fabre M?dicament
14.8. Antares Pharma, Inc.
14.9. CMS Group
14.10. Sandoz Inc.(*LIST NOT EXHAUSTIVE)
15. DATAM INTELLIGENCE
15.1. Appendix
15.2. About Us and Applications
15.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Type
3.2. Market Snippet by Diagnosis
3.3. Market Snippet by Treatment
3.4. Market Snippet by End user
3.5. Market Snippet by Distribution Channel
3.6. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing clinical trials and product launches by the market players are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Lack of awareness about the disorder is expected to hamper in the forecast period.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type Segment
7.2. Mucoepidermoid Carcinoma*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Adenoid Cystic Carcinoma
7.4. Acinic Cell Carcinoma (Acinic Cell Adenocarcinoma)
7.5. Polymorphous adenocarcinoma
7.6. Pleomorphic Adenoma
7.7. Warthin’s Tumor
7.8. Others
8. BY DIAGNOSIS
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
8.1.2. Market Attractiveness Index, By Diagnosis Segment
8.2. Physical exam*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Imaging tests
8.3.1. Magnetic resonance imaging (MRI)
8.3.2. Computerized tomography (CT)
8.3.3. Positron emission tomography (PET)
8.3.4. Ultrasound
8.3.5. Others
8.4. Biopsy
8.5. Others
9. BY TREATMENT
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment Segment
9.2. Surgery*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Radiation therapy
9.4. Chemotherapy
9.4.1. Cisplatin
9.4.2. Mitoxantrone
9.4.3. Doxorubicin (Adriamycin)
9.4.4. Epirubicin (Ellence)
9.4.5. Cyclophosphamide (Cytoxan)
9.4.6. Paclitaxel (Taxol)
9.4.7. Docetaxel (Taxotere)
9.4.8. Vinorelbine (Navelbine)
9.4.9. Methotrexate
9.4.10. Others
9.5. Supportive (palliative) care
9.6. Others
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.1.2. Market Attractiveness Index, By End user Segment
10.2. Hospital*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Clinics
10.4. Ambulatory Surgical Centers
10.5. Diagnostic Centers
10.6. Others
11. BY DISTRIBUTION CHANNEL
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Hospital Pharmacy*
11.2.1. Introduction
11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
11.3. Retail Pharmacy
11.4. Online Pharmacy
11.5. Others
12. BY REGION
12.1. Introduction
12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Product Benchmarking
13.4. List of Key Companies to Watch
14. COMPANY PROFILES
14.1. Bristol-Myers Squibb Company*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Key Highlights
14.1.4. Financial Overview
14.2. LGM PHARMA
14.3. Pfizer Inc.
14.4. Bedford Laboratories
14.5. Baxter
14.6. sanofi-aventis U.S. LLC
14.7. Pierre Fabre M?dicament
14.8. Antares Pharma, Inc.
14.9. CMS Group
14.10. Sandoz Inc.(*LIST NOT EXHAUSTIVE)
15. DATAM INTELLIGENCE
15.1. Appendix
15.2. About Us and Applications
15.3. Contact Us
